Situation
A large US-based health insurance payer was at the beginning stages of standing up a precision medicine initiative. The starting component of the initiative was a pharmacogenomics (PGx) program driven by the payer’s primary goal to reduce adverse drug reactions across its populations. Additionally, the insurance company saw the medical cost reduction, patient safety improvement, and member/customer satisfaction as being key benefits of its investment. Achieving these goals would position them as an innovative and competitive front runner in the precision medical insurance space.